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Pharmacokinetic-Directed Dose Adjustment Is Essential
for Intravenous Busulfan Exposure Optimization:
Findings From a Multi-Center Phase II Study of
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This prospective, multi-center study investigated the
utility of pre-conditioning test pharmacokinetics (PK) of
intravenous busulfan (IV Bu) to optimize dosing in 204
subjects with Hodgkin (n¼64) and B-cell non-Hodgkin
lymphoma (n¼140) at 32 centers in the US and Canada. PK
studies were conducted twice during the study: test PK on
Day -14 to -11 and conﬁrmatory PK on the ﬁrst day of
conditioning, Day -8. The test PK used a 2-hour infusion of
a single IV Bu dose (0.8mg/kg) in order to determine the area
under the concentration-time curve (AUC). The test PKTable 1
AUC Exposure and Clearance from a Test Dose of 0.8 mg/kg IV Bu by Different BM
BMI Category (kg/m2)
BMI (kg/m2)
(Mean  SD)
Clearance (mL/min/
kg) Median (range)
AUC from
<1,000 m
Under Weight (<18.5) 17.9  0.51 2.76 (2.50 - 2.99) 0
Normal (18.5 - 24.9) 22.9  1.63 2.85 (1.95 - 4.39) 10 (18.5
Over Weight (25.0 - 29.9) 27.6  1.48 2.92 (2.15 - 4.11) 23 (33.8
Obese (>30.0) 35.4  5.10 3.16 (2.43 - 4.20) 35 (44.3dosing was based on adjusted ideal body weight (AIBW) for
all patients except for the subjects whose actual BW was less
than or equal to the ideal BW, where actual BW was used.
AIBW was calculated by adding 25% of the difference
between ideal BW and actual BW to ideal BW. The condi-
tioning dose of daily IV Bu was then calculated to achieve
20,000 mM*min as a total AUC. The same individualized Bu
dose was administered over 3 hours once daily from Day -8
to Day -5. If needed, dose was further adjusted on Days -6
and -5 based on conﬁrmatory PK results. VP-16 (1.4 g/m2)
was administered on Day -4, followed by 2.5 g/m2/day of
cyclophosphamide on Days -3 and -2.
Test PK from 204 subjects showed that 6 subjects (2.9%)
had higher AUC than expected (>1,500 mM*min) and 68
subjects (33.3%) had lower AUC (<1,000 mM*min). Therefore,
total AUC would have fallen outside the target range in 74
subjects (36.3%) if PK-directed dose adjustment had not been
performed. The discrepancy between expected and observed
exposure was not predicted by subject height, actual body
weight, body mass index (BMI) or body surface area. For
example, although a greater proportion of patients with high
BMI were underexposed compared with those with normal
BMI, the difference was not signiﬁcant [Table 1]. In addition,
all patients who had AUC>1,500 mM*min had normal or high
BMI. Thus, it is not possible to prospectively identify the
subpopulation which has a risk of suboptimal Bu exposure
and would gain the most beneﬁt from PK-directed dose
optimization.Hence, PK-directeddoseoptimization shouldbe
considered for all subjects when tight regulation of Bu expo-
sure is critical, and should not be limited to subpopulations.
Out of 200 patients whose conﬁrmatory PK results were
evaluable, 190 subjects (95.0%) fell within the target range
(AUC: 20,000 mM*min  20%). Eight (4.0%) and two (1.0%)
patients required dose reductions and increases, respec-
tively, for the last two days of Bu dosing. Again, no predictive
factor was identiﬁed for these patients.
In conclusion, a pre-conditioning small dose of IV Bu
estimated individual PK parameters and predicted Day-8 PK
in 95% of the subjects. This relatively large PK study identi-
ﬁed no factor that could predict outliers linked to Bu
metabolism. Therefore, when Bu exposure has to be tightly
controlled, PK-directed dose optimization should be con-
ducted for all patients.42
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Test Dose of 0.8 mg/kg (n)
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S133Achievement of a complete remission (CR) is considered an
important goal of therapy in multiple myeloma (MM). High
dose chemotherapy with autologous stem cell trans-
plantation (ASCT) was the ﬁrst treatment to reliably produce
CR in MM. Several approaches have been tried to further
increase the CR rate including polychemotherapy prepara-
tive regimens, tandem ASCT, consolidation and/or mainte-
nance therapy. Since there is a dose response effect for
melphalan, we evaluated an alternative single ASCT strategy
using higher dose melphalan at 280 mg/m2 (MEL 280).
Methods: We completed a multicenter, phase II trial of MEL
280 in patients withMMundergoing ASCTafter a median of 1
prior regimen. Twodoses of amifostine (AF) 740mg/m2 IVover
5-15 minutes were administered 24 hour and 15 min before
MEL 280 to ameliorate mucosal toxicity. Between 5/1999 and
10/2003, 58MMpatients (pts) received this highdose regimen
after dexamethasone-based induction regimens. Lenalido-
mide or bortezomib were not used in induction.
Themedian agewas 50 yrs (35-66), 33weremale, median
initial beta 2-microglobulin level was 3.0 mg/L (0.8-22.4).
The subtypes included IgG (n¼ 32), IgA (n ¼15), light chain
(n ¼ 8)and non-secretory (n¼ 3); 67% had Durie Salmon
stage III disease; 90% of pts were chemosensitive to dexa-
methasone-based induction therapy. Median time from
diagnosis to ASCT was 7.5 months.
Toxicity: Bearman critieria were utilized for grading
regimen-related toxicity (RRT): grade 1 mucositis was seen
in 41%, grade 2 in 14% and grade 3 in 1.7%. Other grade 3
toxicities included: lung (1.7%) and renal (1.7%); 1 pt died
from melphalan-induced interstitial pneumonitis; 7% expe-
rienced atrial ﬁbrillation or ﬂutter. Of the 57 evaluable pts, CR
was achieved in 28 (49%), VGPR in 6 (11%), PR in 17 (30%), SD
in 4 (7%) unknown in 1 (1.5%) and progression in 1 (1.5%).
At a median follow-up of 7 yrs, 76% of pts have progressed
and 57% have died. The cause of deathwasMM in 88% (29/33)
and non-relapse causes in 4 (1 lung cancer,1 coronary disease,
1 sepsis and 1 complications of subsequent allogeneic
transplant). The median overall survival (OS) is 67 months
while the median progression-free survival (PFS) is 22
months. PFS and OS at 7 years was 10% and 39% respectively.
Conclusions: MEL 280 + AF is well-tolerated with low
transplant related mortality. Excellent VGPR+CR rates of 60%
were achieved in the pre-novel agent era. However, the high
CR + VGPR rate after ASCT did not translate into an
improvement in PFS/OS from single or tandem ASCT trials in
that era (Barlogie et al. J Clin Oncol. 2010; 28: 1209-14). In
contrast to recent studies showing CR correlates with
improved long term outcomes, MEL 280 dose escalation
increased response depth, however, sustainability of
response is not impacted.43
High Dose Therapy and Autologous Stem Cell
Transplantation Results in Good Outcomes and
Acceptable Toxicities in Elderly Patients with
Non-Hodgkin's Lymphoma
Roni Tamari 1,2, Parastoo Dahi 1,2, Sean Devlin 3,
Jenna Goldberg 1, Paul Hamlin Paul 4, Matthew Matasar 4,
Jocelyn Maragulia 5, Miguel-Angel Perales 1,
Craig H. Moskowitz 6, Craig Steven Sauter 1. 1 Department of
Medicine, Adult Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center, New York, NY; 2 equal
authorship; 3 Department of Biostatistics, Memorial
Sloan-Kettering Cancer Center, New York, NY; 4 Division of
Hematologic Oncology, Memorial Sloan Kettering Cancer
Center, New York City, NY; 5Memorial Sloan-Kettering Cancer
Center; 6 Division of Hematologic Oncology, Memorial
Sloan-Kettering Cancer Center, New York City, NY
Background: High-dose therapy and autologous stem-cell
transplantation (HDT-ASCT) can offer potential long-term
remission or cure in patients with high risk non-Hodgkin's
lymphoma (NHL). Limited experience is available on the
safety and efﬁcacy of HDT-ASCT in elderly patients.
Methods: This is a single-center, retrospective study exam-
ining outcomes of HDT-ASCT for NHL in 145 patients 60 years
and older between January 2001 and December 2010. Clin-
ical data and comorbidities were correlated with outcomes.
Overall survival (OS) and progression-free survival (PFS)
were analyzed according to age at transplant, histology,
hematopoietic cell transplantation comorbidity index (HCT-
CI) and ﬁrst remission versus subsequent remission at the
time of HDT-ASCT.
Results: The median age was 65 (range 60-74). Fifty-nine,
67 and 20 patients were ages 60 - <65, 65 - <70 and >70,
respectively. Patients underwent HDT-ASCT for diffuse large
B-cell lymphoma (DLBCL, n¼57, 39%), mantle cell
lymphoma (MCL, n¼53, 37%) and other NHL subtypes
(n¼35, 24%). HDT-ASCT in ﬁrst remission was performed in
68 patients (47%), mostly with MCL (70%). BEAM and RR-
BEAM were the most common conditioning regimens
(85%). 34 (23%), 35 (24%) and 77 (53%) patients had a low
(0), intermediate (1-2) and high (>3) HCT-CI score at
transplant. Overall, with a median follow-up of 3.2 years
(range 0.2-8.1) for survivors, PFS and OS at 2 years were
71% and 76%, respectively. Age and HCT-CI score did not
affect OS or PFS. Patients with MCL had better outcomes
compared to other NHL histologies with 2 years OS of 90%
versus 65% and PFS of 85% versus 58% respectively. The one
year incidence of progression was 4% in MCL, 28% in DLBCL
and 34% for other NHL histologies. A total of 54 patients
(37%) progressed [24 (44%) DLBCL, 14 (26%) MCL and 16
(30%) others]. Median time to treatment failure was 11.6
months (range 1.3-88). Three (2%) patients died from
transplant complications. High-risk status by HCT-CI was
not associated with TRM. Six patients (4%) developed
secondary myelodysplastic syndrome (MDS) at a median of
40 months (range 5-83).
Conclusion: In this large cohort of elderly patients with NHL
who underwent HDT-ASCT, we demonstrate that this inter-
vention is feasible, tolerable, and effective, and results in
similar disease control and survival as in younger historical
controls. Our data suggest that age alone is not predictive of
post transplant outcomes and therefore should not be used
to preclude HDT-ASCT in elderly.
